Search company, investor...

Founded Year

2016

Stage

Series A | Alive

Total Raised

$22.23M

Last Raised

$20.67M | 8 mos ago

About Alloplex Biotherapeutics

Alloplex Biotherapeutics is exploring the order combinatorial space of immunomodulators to develop an anti-tumor vaccine. It offers preclinical research, organoid data analysis, research summaries, and more. The company was founded in 2016 and is based in Woburn, Massachusetts.

Headquarters Location

300 Trade Center Suite 6580

Woburn, Massachusetts, 01801,

United States

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo
You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Alloplex Biotherapeutics Patents

Alloplex Biotherapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immune system
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/11/2020

11/30/2021

Clusters of differentiation, Immune system, Immunology, Human cells, Transcription factors

Grant

Application Date

6/11/2020

Grant Date

11/30/2021

Title

Related Topics

Clusters of differentiation, Immune system, Immunology, Human cells, Transcription factors

Status

Grant

Latest Alloplex Biotherapeutics News

Cellular Immunotherapy for Hematological Malignancy and Solid Tumor by Alloplex Biotherapeutics for Squamous Cell Carcinoma: Likelihood of Approval

Feb 27, 2023

Cellular Immunotherapy for Hematological Malignancy and Solid Tumor is under clinical development by Alloplex Biotherapeutics and currently in Phase I for Squamous Cell Carcinoma. According to GlobalData, Phase I drugs for Squamous Cell Carcinoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Cellular Immunotherapy for Hematological Malignancy and Solid Tumor’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Cellular Immunotherapy for Hematological Malignancy and Solid Tumor overview Cellular therapy is under development for the treatment of hematological malignancies including  multiple myeloma, lymphoma, and chronic lymphocytic leukemia and solid tumors including squamous cell carcinoma, ovarian cancer, bladder cancer, transitional cell cancer (urothelial cell cancer), pancreatic cancer. It is administered through intravenous route. It comprises of ex vivo activated autologous peripheral blood mononuclear cells (PBMC). Alloplex Biotherapeutics overview Alloplex Biotherapeutics., is a biotechnology company developing an off-the-shelf anti-tumor vaccine. The company is headquartered in United States. For a complete picture of Cellular Immunotherapy for Hematological Malignancy and Solid Tumor’s drug-specific PTSR and LoA scores, buy the report here. Subscribe to our Newsletter

Alloplex Biotherapeutics Frequently Asked Questions (FAQ)

  • When was Alloplex Biotherapeutics founded?

    Alloplex Biotherapeutics was founded in 2016.

  • Where is Alloplex Biotherapeutics's headquarters?

    Alloplex Biotherapeutics's headquarters is located at 300 Trade Center, Woburn.

  • What is Alloplex Biotherapeutics's latest funding round?

    Alloplex Biotherapeutics's latest funding round is Series A.

  • How much did Alloplex Biotherapeutics raise?

    Alloplex Biotherapeutics raised a total of $22.23M.

  • Who are the investors of Alloplex Biotherapeutics?

    Investors of Alloplex Biotherapeutics include HanAll Biopharma, Daewoong Pharmaceutical and U.S. Small Business Administration.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.